Related Experiment Video
Updated: Jan 26, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
[Progression of Chronic Heart Failure: Prognostic Criteria and Non-Drug Prevention]
E R Kurlyanskaya1, T L Denisevich1, A G Mrochek1
1Republic Scientific and Practical Center "Cardiology", Minsk.
Insights
This study developed risk models and non-drug prevention strategies to reduce chronic heart failure (CHF) progression. Applying these interventions significantly lowered CHF severity class increases from 11.7% to 2.2%.
Area of Science:
- Cardiology
- Public Health
Background:
- Chronic heart failure (CHF) is a progressive condition requiring effective management strategies.
- Understanding the frequency and risk factors for CHF progression is crucial for developing targeted interventions.
Purpose of the Study:
- To determine the frequency of chronic heart failure (CHF) progression over 24 months.
- To develop multifactorial risk models for CHF progression.
- To establish non-drug secondary prevention measures for CHF.
Main Methods:
- A cohort of 531 patients with functional class (FC) I-III CHF was studied.
- Clinical, instrumental, and laboratory investigations, including NT-proBNP, were performed.
- Patient data was collected using AUDIT and Morisky Green questionnaires.
Main Results:
- The 24-month CHF progression rate was 11.7%. Key progression factors included myocardial infarction history and low treatment adherence.
- Specific risk factors for FC I to II progression were identified (e.g., age >74, obesity, hypertension, alcohol intake).
- Multifactorial risk models demonstrated high prognostic accuracy (86.3% for FC I, 85.5% for FC II). A non-drug prevention program reduced progression to 2.2% in high-risk patients.
Conclusions:
- The combined use of risk assessment scores and a non-drug prevention program effectively reduced CHF severity class progression.
- This approach lowered the frequency of CHF class increases from 11.7% to 2.2%.
Purpose:
to study frequency of progression of chronic heart failure (CHF), to develop multifactorial models for evaluation of risk of progression, and measures of non-drug secondary prevention of CHF.
Materials And Methods:
We included in this study 531 patients with functional class (FC) I-III CHF (FC I - n=254, FC II - n=255, FC III - n=22). Examination included clinical-instrumental, clinical-functional, and laboratory (with determination of NT-proBNP concentration) investigations, use of the AUDIT and Morisky Green questionnaires.
Results:
Rate of CHF progression for 24 months was 11.7 % (FC I - 16.1, FC II - 7.8, FC III - 4.5 %). Irrespective of FC significant factors of CHF progression were history of myocardial infarction, and low adherence to treatment. Additional prognostic criteria of increase of CHF FC I to FC II were age >74 years, excessive body mass, disturbance of carbohydrate metabolism, arterial hypertension, and frequent intake of alcohol. FC II CHF progression was associated with such factors as type 2 diabetes, 3‑degree arterial hypertension, permanent atrial fibrillation, and smoking. Using these prognostic criteria, we developed multifactor models, based on which scales for assessing the risk of FC I and II CHF progression were created. These models demonstrated high accuracy of prognosis and good reproducibility (on independent test samples of patients with CHF FC I and FC II prognostic accuracy was 86.3 и 85.5 %, respectively). We also developed a program of secondary non-drug prevention of CHF progression, with inclusion of structured dynamic education of patients with organization of control and self-control of knowledge quality. After this therapeutic education progression CHF in high risk patients was 2.2 %.
Conclusion:
Complex application of scores for evaluation of risk of FC I-II CHF progression and the program of secondary non-drug prevention determined lowering of frequency of increases of class of CHF severity from 11.7 to 2.2 %.
More Related Videos
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
07:41Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
Related Concept Videos
Heart Failure Drugs: Diuretics
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure